Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
Enveric Biosciences Inc (NASDAQ:ENVB), a biotechnology company focused on neuropsychiatric treatment development, has secured five new U.S. patents for its EVM301 portfolio.
This latest additions bring Enveric’s total to nine issued U.S. patents, enhancing the intellectual property surrounding its library of neuroplasticity-focused compounds aimed at mental health conditions.
“The addition of these patents not only bolsters Enveric’s efforts in neuropsychiatric disorders but also provides exciting opportunities to explore the therapeutic potential of our compounds in a variety of other medical fields,” Dr. Joseph Tucker, CEO of Enveric told Benzinga exclusively.
See Also: Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
The newly patented …